EG-Colon Blood Test-E1 Early-Stage Colorectal Cancer Blood Test

Model: EG-Colon Blood Test-E1

Booth No: M710

Characteristic

Technology Overview：
EG BioMed has developed a non-invasive, high-throughput circulating cell-free DNA (cfDNA) analysis platform that integrates fully automated cfDNA extraction with high-sensitivity blood testing for colorectal cancer. Powered by proprietary high-specificity methylation probes and quantitative PCR (qPCR) analysis, this platform leverages precise DNA methylation biomarkers to enable both early detection and longitudinal monitoring of colorectal cancer.
The entire process is standardized and automated, requiring only 8 milliliters of peripheral blood with no invasive procedures. Results with high sensitivity and specificity can be delivered in as little as two business days. This platform is well-suited for large-scale clinical implementation and serves as a valuable tool for diagnostic support, prognosis assessment, and ongoing disease monitoring. The technology has been granted a patent in Taiwan and is currently under active application in multiple countries, offering a low-risk and promising new option for the early detection and long-term management of colorectal cancer.

Clinical Applications：
•Early detection in high-risk populations
Suitable for individuals with a family history of colorectal cancer, chronic intestinal inflammation, previous adenomas, or those aged 50
and above.
•Post-surgical and post-treatment follow-up
Helps monitor for recurrence or residual disease. Can be used for regular follow-up and supports personalized treatment planning.
•Complementary tool when colonoscopy or imaging is inconclusive
Provides DNA methylation-based molecular information to support clinical decision-making when traditional tools yield unclear results.

Key Advantages：
•Simple blood draw with no invasive procedures required, ensuring high patient acceptance
•Automated workflow delivers fast results with minimal human error
•Repeatable and suitable for regular follow-up, supporting long-term tracking and treatment evaluation
•Built on patented probes and a standardized platform, offering strong scalability and global application potential

Clinical Performance：
The test has been clinically validated for colorectal cancer across all stages (Stage I–IV), with strong overall performance:
• Sensitivity: 93.3%
• Specificity: 93%
• Overall accuracy: 93%
• Clinical sample size: Over 100 cases analyzed

Patent Strategy & Global Expansion：
EG BioMed began patent development for this technology in 2021. We received our Taiwan invention patent in 2023, and patent applications in the EU, United States, Australia, and other countries are currently under review. This global IP strategy forms a regulatory and competitive foundation for international clinical deployment and future licensing partnerships.

Colorectal Cancer Risk Snapshot：
According to data from Taiwan’s Ministry of Health and Welfare and the U.S. National Cancer Institute:
•1 in 13 people will be diagnosed with colorectal cancer during their lifetime
•90% of colorectal cancer cases occur in individuals over 50 years old
•Regular screening is strongly recommended for early detection and timely intervention

At EG BioMed, we believe this technology is more than just an innovation—it’s a practical tool for everyday health management. Whether for high-risk individuals or post-treatment patients, this test empowers users to detect changes early and proactively safeguard their health.